Literature DB >> 11000472

Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine.

V Huter1, A Hensel, E Brand, W Lubitz.   

Abstract

Pigs immunized with Actinobacillus pleuropneumoniae ghosts or a formalin-inactivated bacterin were found to be protected against clinical disease in both vaccination groups, whereas colonization of the lungs with A. pleuropneumoniae was only prevented in ghost-vaccinated pigs. Bacterial ghosts are empty cell envelopes created by the expression of a cloned bacteriophage lysis gene and, unlike formalin-inactivated bacteria, suffer no denaturing steps during their production. This quality may lead to a superior presentation of surface antigens to the immune system. Analysis by SDS-PAGE and immunoblotting of the two vaccine preparations revealed different contents of antigenic proteins. In order to better understand the immunogenic properties of A. pleuropneumoniae ghosts and formalin-inactivated bacteria, we compared the serum antibody response induced in both treatment groups. Immune sera were tested on whole cell antigen or purified virulence factors including outer membrane protein preparations (OMPs), outer membrane lipoprotein OmlA1, transferrin binding proteins (TfbA1, TfbA7 and TfbB) and Apx toxins (ApxI, II and III). SDS-PAGE and immunoblots revealed no specific antibody response against the single virulence factors tested in any vaccinated animal. The two vaccination groups showed different recognition patterns of whole cell antigen and OMP-enriched preparations. A 100 kDa protein was recognized significantly stronger by ghost-vaccinated pigs than convalescent pigs. This unique antibody population induced by ghosts could play a determining role in the prevention of lung colonization. The same 100 kDa antigen was recognized by ghost-sera in homologous as well as heterologous serotype A. pleuropneumoniae protein preparations. Indications for a crossprotective potential in the ghost vaccine were supported by studies on rabbit hyperimmune sera.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000472     DOI: 10.1016/s0168-1656(00)00310-2

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  8 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge.

Authors:  Ulrike Beate Mayr; Christoph Haller; Wolfgang Haidinger; Alena Atrasheuskaya; Eugenij Bukin; Werner Lubitz; Georgy Ignatyev
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 3.  The Bacterial Ghost platform system: production and applications.

Authors:  Timo Langemann; Verena Juliana Koller; Abbas Muhammad; Pavol Kudela; Ulrike Beate Mayr; Werner Lubitz
Journal:  Bioeng Bugs       Date:  2010 Sep-Oct

4.  Protection of piglets by a Haemophilus parasuis ghost vaccine against homologous challenge.

Authors:  Mingming Hu; Yanhe Zhang; Fang Xie; Gang Li; Jianjun Li; Wei Si; Siguo Liu; Shouping Hu; Zhuo Zhang; Nan Shen; Chunlai Wang
Journal:  Clin Vaccine Immunol       Date:  2013-03-27

5.  Protective efficacy by various doses of Salmonella ghost vaccine candidate carrying enterotoxigenic Escherichia coli fimbrial antigen against neonatal piglet colibacillosis.

Authors:  Jin Hur; John Hwa Lee
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

Review 6.  Harnessing the potential of bacterial ghost for the effective delivery of drugs and biotherapeutics.

Authors:  Aditya Ganeshpurkar; Ankit Ganeshpurkar; Vikas Pandey; Abhishek Agnihotri; Divya Bansal; Nazneen Dubey
Journal:  Int J Pharm Investig       Date:  2014-01

7.  Subcutaneous Immunization of Dogs With Bordetella bronchiseptica Bacterial Ghost Vaccine.

Authors:  Abbas Muhammad; Johannes Kassmannhuber; Mascha Raucher; Alaric A Falcon; David W Wheeler; Alan A Zhang; Petra Lubitz; Werner Lubitz
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

8.  Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.

Authors:  Aleksandra Inic-Kanada; Marijana Stojanovic; Simone Schlacher; Elisabeth Stein; Sandra Belij-Rammerstorfer; Emilija Marinkovic; Ivana Lukic; Jacqueline Montanaro; Nadine Schuerer; Nora Bintner; Vesna Kovacevic-Jovanovic; Ognjen Krnjaja; Ulrike Beate Mayr; Werner Lubitz; Talin Barisani-Asenbauer
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.